£ 2000 invested in Penny Antle Encle Indeed the Ways in the last 3 months now will be important …

Penny part was called Angle (Lese: Agl) rotten back into my portfolio life. I remember that I did this at the same time last year, before death in the market for $ 50m-cap. It must be something to prepare for the new year.

As I wrote, there is a price for 16.4p, 111% higher than before November. This means that the investor who is partner who puts two cupbear back then will now be sitting about £ 4,220. Good.

Only the amount of hundreds of pounds, however, my gross grooming under that. However, I will not complain, and I hope the sharing price can be more, later.

What’s angle?

This small diagnostic company is especially useful in liquid biopsies – non-incoming blood tests that can find cancer cells or tumor DNA. This can help doctors check cancer, check the treatment, and look to see if the disease has returned.

Angle’s Penonselizing BioPSY System of Passortix Animals. This device separates cells and captures the tumor cells (CTCs) from blood samples. It is increasingly recognized as technology that converts a game into an emerging field of actual cancer.

There are only a few interesting things that you can realize here. First, it is protected by the technical ownership of the CTC-harvesting company and has already been cleaned by FDA for use in breast cancer. This is therefore risking risk investment in company technology (applies).

In 2024, it signed two deals with it Astrazeneca with one with a Japan’s pharma company Eisai. This is supporting clinical exams and cancer improvement.

Angle also works in the following generation skills the more perfect idea of ​​the height of cancer. In 29 January, he announced successful results from two new travel, using a biotech company Displacictplatform platform. As a result, follow-up of the DNA sequence has provided all its European Organization for Cancer Cancer research at 6 February receiving findings!

CEO Andrew Newland said: “We see a great opportunity for both angle and Ilvin to work together. “

Finally, the global biopypy market in the world is already great and grows. According to Fortune Business InsiSi, it is expected to grow from $ 9.63bn at 2024 to $ 58bn in 2032.

Risk Galore

Now, there are some important dangers here. Although It Expects 2024 Revenue to Have Increased 31% Year On Year £ 2.9m, IT Also Guiding for a Loss of £ 20.1m in 2023).

And when the company that formed a loss, the cash, adequate for up to 2026, another donation is always possible. That would be the ends of having shares.

Chance to invest asymmetric

Nevertheless, I am very happy to see how the future brings angle pivots from trading instruments to provide for chip-Chip-Chip-Chip-Chip-Chip-Chip-Chip-Chip-Chip-Chip-instra.

According to current predictions, income is expected to grow 49% by 2025 to $ 4.3m, and 68% reach £ 7.26m in 2026 in 2026. However, if cancer tests use their technology forward, late stage studies, income can explode.

Indeed, angle means that comes one Category 3 contract can quickly press the company to become a cash flow.

My thinking is I can handle a few hundred years if things turn paint painted. But if the failure of the failure, the failure was successful, the rewards can be too big in this pen space.